ArticleBlood advances2025
Androgen receptor signaling as a new target for intervention in acute myeloid leukemia.
Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- AR expression in AML cells is same in female vs male patients.Blood advances · 2026Article
- Similar androgen receptor expression in male and female AML.Blood advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractIn addition to their role in development, sex hormones and their cognate receptors play an important role in various malignancies. Using a murine model of human mixed lineage leukemia-acute leukemia fused gene from chromosome 9 (MLL-AF9)-induced acute myeloid leukemia (AML), we discovered that high androgen receptor (AR)-expressing leukemia initiating cells (LICs), when transferred into either male or female recipients, produced more severe disease than low AR-expressing LICs. AR expression was significantly increased in female LICs when compared with male LICs. This difference was confined to the LICs and was not present in normal bone marrow cells. AML cells from both sexes relied on AR signaling via different mechanisms; females had high AR levels with low ligand levels and males had low AR levels with high ligand levels. AR expression was linked to the ephrin type-A receptor 7 (EPHA7)-associated PI3K/AKT/mTOR and SRC/HIF-1α pathways. The use of the 2 United States Food and Drug Administration-approved drugs for prostate cancer, namely ARN509, an AR antagonist, and finasteride, which inhibits the pathway that produces dihydrotestosterone, led to significant remission with increased survival of the AML mice. ARN509 and finasteride also showed proapoptotic effects in patient-derived AML cells and in a humanized AML NOD scid gamma (NSG) mouse model. These data support a drug repurposing effort for the use of antiandrogen therapy to improve the efficacy of AML treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.